Flinn Receives $20 million to Automate the Product Lifecycle in MedTech and Pharma with AI

Flinn, leading the way in medtech compliance, led by Markus Mueller, Bastian Krapinger-Ruether, Hasib Samad, MBA, and the team, has raised $20 million in additional funding led by HV Capital, followed by US-based healthcare specialist BHI - Bertelsmann Healthcare Investments, with continued support from existing investors Cherry Ventures, Speedinvest, and SquareOne.

With the new funding, Flinn will expand its platform across the full MedTech and Pharma lifecycle, from research and development to commercial and post-market processes, while strengthening its presence in Europe and entering the U.S. market to support scalable, compliant, and cost-efficient healthcare innovation.

Healthcare costs are rising under pressure from aging populations, complex therapies, and administrative inefficiencies, straining public budgets and increasing the risk of reduced access or higher out-of-pocket expenses. Although medical devices and pharmaceuticals can help curb costs through automation, advanced diagnostics, and personalized treatments, strict regulatory and quality requirements slow innovation and raise lifecycle compliance costs. Flinn aims to address this challenge.

Flinn is reshaping how regulated MedTech and Pharma companies manage quality and compliance through AI-driven software that automates regulatory workflows, data evaluation, and reporting, replacing manual document-heavy processes with scalable systems.

By embedding automation into regulatory and quality functions, manufacturers gain higher efficiency, shorter development cycles, and full compliance without compromising patient safety, turning a traditional bottleneck into a competitive advantage focused on innovation.

Leading MedTech companies, including Carl Zeiss, Philips, and Paul Hartmann, use Flinn to manage increasing regulatory complexity while maintaining high-quality standards across global markets.

According to Stefan Fischer, automating recurring compliance and evaluation tasks enables more consistent operations across regions and allows teams to focus on higher-value work as regulatory requirements continue to expand.

With an additional $20 million in funding, Flinn plans to extend automation beyond regulatory and post-market solutions into earlier development and commercial stages, creating a unified compliance and quality backbone across the full medical product lifecycle.

The expansion is accompanied by international growth, supported by the global networks of HV Capital and Bertelsmann Investments across Europe and the United States.

Regulatory and quality processes have become major cost drivers across the medical product lifecycle, according to Bastian Krapinger-Rüther of Flinn. The company’s software replaces manual document-heavy workflows with scalable automated systems and will extend this infrastructure to additional lifecycle stages to support global manufacturers.

Flinn demonstrates strong commercial traction, positive customer feedback, and a clear product vision, according to Felix Klühr of HV Capital, who highlighted the team’s speed, conviction, and commitment to MedTech customers as key differentiators heading into the company’s next phase.

At Bertelsmann Healthcare Investments, Tim Schneider cited the founding team’s MedTech expertise and rapid execution in regulated products as key reasons for backing Flinn, highlighting a clear opportunity in the U.S. market and plans to support the company’s expansion and scaling there.